The share of the biopharma company fell up to 5 percent after a foreign institutional investor, Ontario Inc is intend to sell 3.4 percent equity shares from it total holding via block deal.
With a market capitalization of Rs 14,635.28 crore, the shares of Concord Biotech Ltd were trading at Rs 1,398.95 per share, decreasing around 3 percent as compared to the previous closing price of Rs 1,442.30 apiece.
As March 2024, a foreign institutional investor, Ontario Inc holds 26.40 lakh equity shares which is equivalent to 5.39 percent in Concord Biotech Ltd, however, Ontario Inc intend to sell 37 lakh share which is equivalent to 3.4 percent in the company. This implied a total transaction value of Rs 519 crore. CNBC reported.
Looking into Concord Biotech’s financial performance, revenue increased by 17 percent from Rs 273 crore in Q3 FY23 to Rs 319 crore in Q3 FY24. During the same period, net profit increased by 3 percent, from Rs 94 crore to Rs 97 crore.
The company files 7 new DMF’s across Europe, Malaysia, Canada, Australia, Brazil & Taiwan with 22 product registration approvals received across various emerging markets across Asia, Africa & LATAM.
The company reported return ratios in the recent financial year with a return on equity (ROE) of 19.97 percent and a return on capital employed (ROCE) of 26.44 percent. In contrast, the net profit margin (NPM) was 29.96 percent in the fiscal year.
In the company’s recent shareholding pattern, promoters own 44.08 percent while Retail shareholders own a 40.96 percent stake in the company and domestic Institutional Investors own a 8.47 percent stake.
Concord Biotech Limited is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through Fermentation and semi-synthetic processes and finished formulations.
Written by:- Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
